Ratings Surperformance

Trader
-
Investor
Global
-
Quality
ESG MSCI
-

Ratings ESG MSCI

Ratings Harvard Bioscience, Inc.: Strengths and Weaknesses

  • Overall, the company has poor fundamentals for a medium to long-term investment strategy.
  • According to MSCI, the company's ESG score for its industry is poor.
Highlights: Harvard Bioscience, Inc.
  • The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
Weaknesses: Harvard Bioscience, Inc.
  • The company's earnings growth outlook lacks momentum and is a weakness.
  • As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
  • Low profitability weakens the company.
  • In relation to the value of its tangible assets, the company's valuation appears relatively high.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
  • Most analysts recommend that the stock should be sold or reduced.
  • The appreciation potential seems limited due to the average target prices set by the analysts covering the stock.
  • Over the past twelve months, analysts' opinions have been revised negatively.

Rating Financials

Harvard Bioscience, Inc. SectorUnited States

Fundamentals

Growth

Revenue growth

EPS growth

FCF growth

Profitability

EBITDA Margin

EBIT Margin

Net Margin

Capital Efficiency

ROA

ROCE

-

ROE

Financial Health

-

Gearing

-

Leverage

-

Capital Intensity

Balance sheet growth

Long Term balance sheet growth

Long term revenue growth

Long term EPS growth

More ratings

Rating Valuation

Harvard Bioscience, Inc. SectorUnited States

Global Valuation

-

Enterprise Value

-

EV/Revenue

-

EV/EBITDA

-

EV/FCF

-

Equity Valuation

-

P/E

-

PBR

Dividend Yield

-

EV/EBIT

-

CAPEX/Revenue

More ratings

Rating Consensus

Harvard Bioscience, Inc. SectorUnited States

Consensus

Analysts' buy/sell recommendations

Analysts' recommendations evolution (1 year)

Analysts' recommendations evolution (4 months)

Analysts' target price

Analysts' target price evolution (1 year)

Analysts' target price evolution (4 months)

Analysts' recommendations evolution (7 days)

Target Price evolution (7 days)

More ratings

Rating Business Predictability

Harvard Bioscience, Inc. SectorUnited States

Visibility

-

Analysts' coverage

Financial estimates divergence

-

Analysts' recommendations divergence

Analysts' Target price divergence

-

Surprise rates

Rating Revisions

Harvard Bioscience, Inc. SectorUnited States

Financial revisions

Revenue revisions (1 year)

Revenue revisions (4 months)

EPS revisions (1 year)

EPS revisions (4 months)

EPS revisions (7 days)

Revenue revisions (7 days)

More ratings


Capi.($) Investor ESG MSCI Fundamentals Financial revisions Global Valuation Visibility Consensus
37.97M - - -
242B
BBB
150B
A
138B
BBB
61.74B
BBB
49.08B
AAA
47.43B
BBB
47.3B
AAA
44.25B
AAA
41.78B
AAA
Average 82.27B
AA
Weighted average by Cap.
AA
  1. Stock Market
  2. Stocks
  3. HBIO Stock
  4. Ratings Harvard Bioscience, Inc.